Kingskin salicylic acid wart remover recalled for manufacturing deviations
Pharmadel recalled 20,048 bottles of Kingskin salicylic acid topical wart remover due to manufacturing process deviations. The product was distributed in Delaware, and no illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall initiated by manufacturer due to cGMP deviations. No reported illnesses, injuries, or specific identified safety hazard. Per the rubric, voluntary precautionary recalls with theoretical hazards and no documented harm are rated Moderate (2).
Plain-English summary
Kingskin is a topical salicylic acid product used to remove common warts, manufactured by Pharmadel, LLC. The product was distributed in 0.50 oz (15 mL) bottles in Delaware. The recall affects approximately 20,048 bottles across two affected lots: KSE-01 (expiration October 2026) and KSE-02 (expiration February 2027).
Pharmadel initiated a voluntary recall in April 2025 due to identified Current Good Manufacturing Practice (cGMP) deviations. The FDA classified this as a Class II recall. The recall was concluded on January 8, 2026.
No illnesses or injuries have been reported in association with this product. Consumers with health concerns should consult a healthcare provider.
The recalled product
- Product
- KINGSKIN (SALICYLIC ACID)
- Brand
- KINGSKIN
- Manufacturer
- Pharmadel, LLC
- Category
- Drug — Topical OTC
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot
- expiry: KSE-01
- EXP: OCT 26
- KSE-02
- EXP: FEB 27
Distribution
Distributed in 1 state:
- DE
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27